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Objectives This study sought to determine the utility of quantitation of right ventricular (RV) function in predicting RV failure
in patients undergoing left ventricular assist device (LVAD) implantation.
Background Clinical evaluation alone seems insufficient for predicting RV failure, an important cause of morbidity and mor-
tality after LVAD implantation.
Methods Clinical, hemodynamic, and echocardiographic data were collected on 117 patients undergoing LVAD implantation.
Standard pre-procedural echocardiographic RV measurements were supplemented by velocity vector imaging of RV
free wall longitudinal strain. RV failure was defined as the need for placement of an RV assist device, or the use of
inotropic agents for 14 days. Receiver operating characteristic curves were derived, with resampling to generate
valid estimates of prediction accuracy. A net reclassification index was calculated for comparison of risk scores.
Results RV failure occurred in 47 of 117 patients (40%). There was a significant difference in peak strain between pa-
tients with and without RV failure (–9.0% vs. –12.2%; p  0.01). A peak strain cutoff of –9.6% predicted RV fail-
ure with 76% specificity and 68% sensitivity. In a multivariate logistic regression analysis including variables
from the established Michigan RV risk score, peak strain remained an independent predictor of RV failure. RV
strain was incremental to the Michigan risk score as a predictor of RV failure (area under the receiver operating
characteristic curve: 0.77 vs. 0.66; p  0.01). The net reclassification index with strain was 10.4%.
Conclusions Reduced RV free wall peak longitudinal strain was associated with an increased risk for RV failure among pa-
tients undergoing LVAD implantation. (J Am Coll Cardiol 2012;60:521–8) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.073Implantation of a left ventricular assist device (LVAD) is
increasingly used in the treatment of end-stage heart failure
(1). Unfortunately, as LVAD placement does not augment
the function of the right ventricle (RV), unanticipated RV
failure remains a significant clinical problem (2), with rates
varying between 5% and 44%, influenced by differing criteria
and populations (3–16). RV failure is characterized by
reduced end-organ function from a low-flow state and/or
increased systemic venous pressures. No uniform definition
of severe RV failure exists, but a common definition is the
need for placement of a right ventricular assist device
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Starling has received research support and modest honoraria from Thoratec. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose.Manuscript received October 3, 2011; revised manuscript received January 13,
2012, accepted February 18, 2012.(RVAD) or the use of intravenous inotropes for 14 days
post-operatively (5,6,12,17).
See page 529
The poor prognosis of RV failure after LVAD insertion
may be improved if patients at risk are appropriately
identified in advance and have biventricular mechanical
support placed at the time of initial surgery (18). Unfortu-
nately, risk scores for RV failure (3–15), including scoring
systems that combine clinical, hemodynamic, and laboratory
parameters (8,9,15), have not been rigorously tested in
populations outside those in which they were derived.
Echocardiographic parameters have been reported to pro-
vide valuable information about the risks of RV failure
(9–11,13,14). Two-dimensional global strain imaging is a
new echocardiographic technique for assessing systolic per-
a
E
r
r
g
w
v
d
s
u
s
S
o
s
s
t
l
m
t
522 Grant et al. JACC Vol. 60, No. 6, 2012
RV Assessment and Ventricular Assist Devices August 7, 2012:521–8formance based on the sum of
regional deformation. Changes in
RV strain have been shown to be
valuable in predicting clinical out-
comes in heart failure (19). In this
study, we sought to evaluate the
utility of RV strain for the predic-
tion of RV failure after LVAD
implantation.
Methods
Patient selection. We studied
data from consecutive patients who underwent continuous-
flow LVAD placement at the Cleveland Clinic Foundation
from May 1, 2007, until April 30, 2011. These devices
included the HeartMate II (Thoratec, Pleasanton, Califor-
nia) and the HeartWare HVAD (HeartWare, Oakville,
California). Patients undergoing replacement of an existing
LVAD, or with a pre-operative plan for biventricular
support with a total artificial heart or RVAD, or who were
supported with extracorporeal membrane oxygenation at the
time of their echo were excluded. Patients were also ex-
cluded if they had no archived pre-operative transthoracic
echocardiogram, or if image quality was deemed insufficient
to perform analysis of RV function. The study protocol was
approved by the institutional review board at the Cleveland
Clinic.
Clinical data. Baseline clinical, demographic, hemody-
namic, and laboratory data were gathered prospectively in
the electronic record and entered into the ventricular assist
Abbreviations
and Acronyms
AUC  area under the
curve
LV  left ventricle
LVAD  left ventricular
assist device
RV  right ventricle
RVAD  right ventricular
assist device
Figure 1 Pre- and Post-Operative Images in a Patient With RV Fa
Patient in whom right ventricle (RV) failure developed post-operatively and required righ
transthoracic echocardiogram showing a peak RV free wall strain of –7.3%. (B) RV
(C) Increased RV diameter on TEE before RVAD implantation.device database. The electronic record was used to identify
patients who underwent RVAD placement, as well as to
determine mortality and duration of hospital stay. Inotrope
and vasopressor use was also verified by review of the
electronic medication ordering system.
The Michigan RV risk score (8) was calculated for each
patient. This score assigns points based on 4 variables, with
vasopressor use adding 4 points, creatinine2.3 mg/dl adding
3 points, bilirubin 2 mg/dl adding 2.5 points, and aspartate
aminotransferase80 IU/dl adding 2 points. A higher score is
ssociated with a greater risk for RV failure (8).
chocardiographic assessment. Pre-operative transtho-
acic echocardiograms were reviewed and analyzed by a
eader blinded to clinical outcomes. Standard echocardio-
raphic measurements of the RV were made in accordance
ith current guidelines (20), including the maximal trans-
erse RV end-diastolic dimension, end-systolic and end-
iastolic RV areas, and fractional area change. Maximal
ystolic excursion of the tricuspid annulus was measured
sing 2-dimensional images.
Longitudinal strain was measured retrospectively using
tandard commercial software (Velocity Vector Imaging,
iemens AG, Erlangen, Germany). The endocardial border
f the RV was traced from an apical 4-chamber view, and
train curves were generated automatically for each of 6
egments. The peak strain for the 3 segments corresponding
o the RV free wall was averaged to produce a global
ongitudinal strain measurement (Figs. 1 and 2). Strain
easurements were carried out retrospectively as a part of
he study protocol, and as such were not available when
ricular assist device (RVAD) implantation. (A) RV strain curve from pre-operative
olic diameter on pre-operative transesophageal echocardiography (TEE).ilure
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August 7, 2012:521–8 RV Assessment and Ventricular Assist Devicesclinical decisions were made. To assess interobserver vari-
ability, global longitudinal RV strain was measured by 2
independent blinded investigators in a subgroup of 20 study
patients. Intraobserver variability was measured by repeated
assessment of strain in the same group of patients by 1
investigator at a separate time.
Outcomes. Patients were divided into 2 groups based on
the occurrence of post-operative RV failure. RV failure was
defined as unplanned insertion of an RVAD or the use of an
intravenous inotrope for 14 days post-operatively.
Statistical analysis. Pre-operative variables were compared
between the 2 groups using JMP Pro 9.0 (SAS Institute Inc.,
Cary, North Carolina). Continuous variables were compared
using the unpaired t test for normally distributed variables and
he Wilcoxon rank sum test for non-normally distributed
ariables. The chi-square or Fisher exact test was used for
categorical variables. A p value of 0.05 was considered signifi-
ant. Univariate regression analysis was performed to calculate an
dds ratio for RV failure for each baseline variable.
Receiver operating characteristic curves were generated and
ompared (21) using MedCalc for Windows 11.6.1 (MedCalc
oftware, Mariakerke, Belgium). Bootstrap estimation with
esampling from 1,000 simulations was used to generate valid
stimates of prediction accuracy. A net reclassification index
as calculated for comparison of risk scores (22).
A series of exploratory models was created by multivariate
ogistic regression to seek the strongest predictors of out-
ome, based on the greatest pseudo-R2. Variables were
ntered allowing 1 variable per 10 events, and were then
referentially removed with p  0.05. Candidate variables
ere selected on clinical grounds (including all components
Figure 2 Pre- and Post-Operative Images in a Patient Without R
Patient in whom right ventricle (RV) failure did not develop. (A) RV strain curve fro
–18.0%. (B) RV diastolic diameter on pre-operative transesophageal echocardiogra
assist device implantation (performed to assess for endocarditis).f the Michigan RV risk score) (8), within the categories of vlinical features, hemodynamics, echo assessment of RV
unction, markers of end-organ function, and therapy.
Interobserver and intraobserver variability in RV strain
easurement were assessed using Bland-Altman analysis
or a selected group of 20 patients.
esults
atient characteristics. Between May 1, 2007, and April
0, 2011, LVADs were implanted in 143 patients at the
leveland Clinic who met the clinical criteria for study
nclusion. Twenty-six patients were excluded on the basis of
issing echocardiographic data or poor image quality, leaving
final study group of 117 patients. Two patients underwent
mplantation with the HeartWare HVAD (HeartWare), and
he other 115 received the HeartMate II (Thoratec).
A comparison of the clinical characteristics of the 117
atients included in the study with those of the 26 patients
ith inadequate images for analysis is shown in Table 1.
part from mean arterial blood pressure, excluded patients
ad a similar risk profile.
utcomes. RV failure occurred in 47 of 117 patients (40%),
ncluding 10 patients who underwent RVAD placement and 37
atients who required inotropes for 14 days. The 1-year mor-
ality rates were 9 of 47 (19%) and 13 of 70 (19%) in the groups
ith and without RV failure, respectively (p  0.94).
ssociations of RV failure. Clinical predictors of RV
ailure included pre-operative inotrope use, bilirubin, car-
iac index, and pulmonary vascular resistance. Univariate
dds ratios for RV failure of clinical and hemodynamic
ilure
operative transthoracic echocardiogram showing a peak RV free wall strain of
EE). (C) Interval decrease in RV size on repeat TEE 28 days after left ventricularV Fa
m pre-
phy (Tariables are shown in Table 2.
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RV Assessment and Ventricular Assist Devices August 7, 2012:521–8Table 3 outlines the association of pre-operative echocar-
diographic parameters with RV failure. RV failure was
associated with subjective assessment of RV function as
moderate to severely reduced (51% vs. 30%; p  0.04) and
ith lower peak longitudinal strain of the RV free wall
–9.0% [interquartile range: –7.3% to 11.4%] vs. –12.2%
interquartile range: –9.5% to –14.9%]; p  0.01).
Using bootstrapping with 1,000 simulations, a receiver
perating characteristic curve (area under the curve [AUC]: 
.70) was used to select an RV strain cutoff of –9.6%
specificity: 76%; sensitivity: 68%) to predict RV failure.
ndependent associations of RV failure. A number of
redictive models were created to seek the strongest predic-
ors of RV failure. Variables were entered into the model 4
t a time (allowing 1 variable per 10 events). When
ombined with the Michigan RV risk score in a multivariate
odel, RV peak longitudinal strain was a significant con-
ributor to the model (Table 4). It remained a significant
ariable in all tested models.
ncremental prediction of RV failure. We then set out to
uantify the added value of RV strain when combined with
he Michigan risk score. In this analysis, an RV peak
ongitudinal strain of –9.6% was assigned a weighting of
.5 points based on the relative odds ratios for RV failure of
Baseline Clinical, Laboratory, and HemodynamicIncluded and Excluded PatientsTable 1 Baseline Clinical, Laboratory, and HIncluded and Excluded Patients
Characteristic
St
Age (yrs) 5
Male 9
Ischemic etiology 4
History of COPD
Previous cardiac surgery 3
Bridge to transplantation 7
Pre-operative mechanical ventilation
Pre-operative IABP/MCS 2
Pre-operative inotrope 7
Cardiopulmonary bypass time (min) 8
Serum sodium (mmol/l) 13
Blood urea nitrogen (mg/dl) 3
Creatinine (mg/dl) 1.2
AST (U/l) 3
Bilirubin (mg/dl) 1
Hemoglobin (g/dl) 11
Prothrombin time INR 1
Heart rate (beats/min) 8
Right atrial pressure (mm Hg)
Mean pulmonary artery pressure (mm Hg) 3
Pulmonary capillary wedge pressure (mm Hg) 2
Mean systemic arterial pressure (mm Hg) 7
Cardiac index (l/min) 2
Pulmonary vascular resistance (WU) 2
RV stroke work index (mm Hg ml/m2 beat) 54
Values are median (interquartile range), n/N (%), or mean  SD.
AST  aspartate aminotransferase; COPD  chronic obstructive p
normalized ratio; MCS  mechanical circulatory support; RV  right vreatinine and bilirubin in our cohort. The Michigan RV uisk score was calculated for each patient and compared with
his modified risk score. Receiver operating characteristic
urves for the Michigan risk score, and the score combined
ith RV strain, are shown in Figure 3. A similar score was
alculated by assigning a weighting of 2.5 points to subjec-
ive echo assessment of RV dysfunction (Fig. 3). There was
significant difference between the AUC for the Michigan
isk score and the combined score with RV strain (AUC:
.66 vs. 0.77; p  0.01). There was no significant difference
etween the AUC for the Michigan risk score and that of a
ombined score using subjective assessment of RV function
AUC: 0.69; p  0.33). Using a cutoff of 3 for the new
core incorporating RV strain, 8 of 45 patients with RV
ailure would be correctly reclassified as “at risk,” and 5 of 68
atients without RV failure would be incorrectly reclassified
s at risk, leading to a net reclassification index of 10.4%.
eliability of RV strain. When peak longitudinal strain
as measured in the same 20 patients by 2 blinded observ-
rs, there was a bias of 0.8% and SD of 2.9%. Intraobserver
omparisons yielded a bias of 0.1% and a SD of 2.8%.
iscussion
he findings of this study indicate that RV strain may be a
racteristics ofynam c Characteristics of
tients
17)
Excluded on the Basis
of Imaging (n  26) p Value
–65) 57.5 (51.5–74) 0.83
(79) 23/26 (88) 0.41
(40) 13/26 (50) 0.36
(7) 2/26 (8) 0.88
(33) 10/26 (38) 0.62
(67) 18/26 (69) 0.80
(5) 0/26 (0) 0.24
(18) 5/26 (19) 0.28
(62) 18/26 (69) 0.54
109) 79 (60–105) 0.18
–137) 134 (130–137) 0.89
–39) 32 (22–48) 0.65
–1.70) 1.41 (1.09–1.62) 0.53
51.5) 27 (21.8–40.8) 0.32
–1.7) 1.0 (0.6–1.5) 0.08
–12.7) 11.2 (9.7–12.8) 0.82
–1.3) 1.2 (1.1–1.5) 0.12
100) 85 (79–100) 0.99
15) 11 (6–18) 0.97
–41) 35 (32–40) 0.29
–26) 23 (16–27) 0.69
–79) 79 (72–85) 0.04
0.59 2.06 0.43 0.96
–4.0) 2.3 (1.8–2.8) 0.94
–741) 501 (390–712) 0.66
ry disorder; IABP  intra-aortic balloon pump; INR  international
lar.Chaemod
udy Pa
(n  1
8 (47.5
2/117
7/70
8/117
9/117
8/117
6/117
1/117
2/117
9 (69–
4 (131
0 (22
7 (1.09
0 (24–
.1 (0.8
.2 (9.7
.1 (1.1
9 (73–
11 (6–
3 (28
0 (17
4 (68
.25
.4 (1.5
2 (367seful pre-operative predictor of RV failure in patients
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August 7, 2012:521–8 RV Assessment and Ventricular Assist Devicesundergoing LVAD implantation—more powerful than any
other echocardiographic parameter studied, including tri-
cuspid annular systolic excursion (14,23) and RV-to-LV
diameter ratio (11). Global longitudinal RV strain was an
independent predictor of RV failure, which was incremental
to a currently used risk model (8,9), correctly reclassifying a
significant number of patients.
RV function in LVAD recipients. After LVAD implan-
tation, adequate RV function is required to permit ante-
Clinical, Laboratory, andHemodynamic Risk F ctor for RV FailureTable 2 Clin cal, Laboratory, andHemodynamic Risk Factor for RV Failure
Characteristic
OR for RV
Failure
95% Confidence
Interval
p
Value
Age 0.98 0.95–1.01 0.13
Male 0.54 0.22–1.32 0.17
Ischemic etiology 1.02 0.48–2.17 0.96
History of COPD 0.47 0.12–1.87 0.36
Previous cardiac surgery 0.65 0.29–1.45 0.32
Bridge to transplantation 0.59 0.27–1.29 0.23
Pre-operative mechanical
ventilation
3.16 0.56–18.20 0.22
Pre-operative IABP/MCS 1.45 0.56–3.75 0.45
Pre-operative inotrope 2.53 1.13–5.68 0.03
Cardiopulmonary bypass time 1.00 0.99–1.01 0.69
Michigan RV risk score (per point) 1.48 1.17–1.91 0.01
Pre-operative vasopressor 2.08 0.44–9.73 0.35
Creatinine 1.42 0.66–3.10 0.36
AST 1.00 1.00–1.01 0.57
Bilirubin 1.68 1.17–2.62 0.01
Serum sodium 0.95 0.88–1.02 0.17
Blood urea nitrogen 1.01 0.98–1.03 0.62
Hemoglobin 1.14 0.92–1.41 0.23
Prothrombin time INR 3.12 0.75–22.2 0.12
Heart rate (per 10 beats/min) 1.16 0.93–1.44 0.17
Right atrial pressure 1.00 0.94–1.06 0.94
Mean pulmonary artery pressure 0.99 0.94–1.04 0.61
Pulmonary capillary wedge pressure 0.96 0.89–1.02 0.20
Mean systemic arterial pressure 0.97 0.92–1.02 0.30
Cardiac index 0.41 0.19–0.82 0.01
Pulmonary vascular resistance 1.45 1.13–1.91 0.01
RV stroke work index
(per 100 mm Hg ml/m2 beat)
0.88 0.77–1.01 0.05
OR  odds ratio; other abbreviations as in Table 1.
Echocardiographic Risk Factor for RV FailureTable 3 Echocardiographic Risk Factor for RV Failure
Echocardiographic Variable No RV Failure
LV end-diastolic dimension (cm) 7.0 1.0
LV ejection fraction (%)* 15 (10 to 20)
Mitral regurgitation (moderate to severe) 33/62 (53)
Subjective RV dysfunction (moderate to severe) 19/63 (30)
Tricuspid regurgitation (moderate to severe) 21/61 (34)
Lateral RV peak longitudinal strain (%) 12.2 (9.5 to 14.9)
RV fractional area change (%) 22.1 8.4
RVEDD-to-LVEDD ratio 0.72 0.15
Tricuspid annular systolic excursion (cm) 1.32 0.29Values are mean  SD, median (interquartile range), or n/N (%).
LV  left ventricular; LVEDD  left ventricular end-diastolic dimension; RVEDD  right ventricular endgrade inflow into the device. RV failure occurs when the RV
provides inadequate output, or when it provides output only
at the expense of high filling pressures. Unfortunately, many
patients undergoing LVAD implantation have some degree
of RV dysfunction prior to surgery, which can put them at
risk for RV failure. In many patients, RV function improves
after implantation, probably because RV afterload is re-
duced by reversal of pulmonary venous hypertension
(16,24). However, complex hemodynamic changes at the
time of LVAD implantation can adversely affect RV func-
tion (25). Increased forward output from the left heart and
LV decompression cause a leftward shift of the interven-
tricular septum, which may interfere with normal RV
mechanics. Post-operative RV distension and increased
filling pressures may result from perioperative use of blood
products and crystalloid, and RV dysfunction may be
exacerbated by intraoperative RV injury (due to poor car-
dioprotection, right coronary air embolus, and/or pulmo-
nary hypertension related to cardiopulmonary bypass [26]).
RV failure has been associated with adverse outcomes,
including mortality. However, the financial cost associated
with implanting an RVAD in all patients makes routine
biventricular support an unacceptable option. Moreover,
biventricular support with both an LVAD and an RVAD
may lead to a greater number of device-related complica-
tions. The majority of RVADs being used for long-term
support are early generation pumps using pulsatile pneu-
matic drive systems. They tend to have larger control
systems and limited portability and carry a greater risk for
mechanical failure and hemolysis (27). These more cumber-
some devices impose greater complexity to long-term care
and may reduce quality of life. Thus, although intervening
prophylactically by placing biventricular support at the time
of initial surgery is more effective than responding with a
“rescue” RVAD (18,26), a selective approach to RVAD
implantation is more desirable than widespread use.
Assessment of RV function. The adequacy of RV function
(and its capacity to respond to a change in loading condi-
tions after LVAD implantation) is difficult to evaluate.
Previous work has highlighted the relevance of markers of
end-organ function and congestion, such as urea, creatinine,
RV Failure OR (95% CI) p Value
6.9 1.1 0.86 (0.58–1.27) 0.45
15 (10 to 25) 1.01 (0.93–1.11) 0.75
24/44 (55) 1.03 (0.70–1.52) 0.89
22/43 (51) 1.56 (1.04–2.34) 0.03
16/44 (36) 1.04 (0.69–1.56) 0.84
9.0 (7.3 to 11.4) 0.84 (0.75–0.92) 0.01
19.4 8.7 0.96 (0.92–1.01) 0.09
0.74 0.17 2.75 (0.24–33.8) 0.42
1.22 0.25 0.26 (0.06–1.05) 0.06-diastolic dimension; other abbreviations as in Tables 1 and 2.
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RV Assessment and Ventricular Assist Devices August 7, 2012:521–8aminotransferases, bilirubin, and prothrombin time. Unfor-
tunately, these markers are not specific to RV dysfunction,
and they may be insensitive as they reflect only the degree of
pre-existing baseline RV failure. Nonetheless, such readily
available parameters continue to be of value, and in our
patients, bilirubin was a strong independent predictor of RV
failure (Table 2).
Pre-operative hemodynamic measures have had variable
predictive power in different studies. In the present work,
cardiac index and pulmonary vascular resistance were both
related to the rate of RV failure. The lower cardiac index in
the patients in whom RV failure developed may have
reflected a group of patients in whom baseline RV dysfunc-
tion was sufficient to limit cardiac output. Those with
greater pulmonary vascular resistance might be less likely to
have an improvement in forward flow when the LV is
Predictive Model for RV Failure, Including Michigan Risk Score andTable 4 Predictive Model for RV Failure, Including Michigan Ri
Variable SD
Michigan Risk score 1.8
Lateral RV peak longitudinal strain, % 4.3
Tricuspid annular systolic excursion, mm 2.8
RV-to-LV diameter ratio 0.16
CI  confidence interval; LV  left ventricle; OR  odds ratio; RV  right ventricle.
Figure 3
Michigan Risk Score With the Addition of
Echocardiographic Assessment of RV Function
by Subjective Reporting and RV Strain
Displayed p values are for the comparison of AUC to the Michigan risk score
alone. AUC  area under the receiver operating characteristic curve;
RV  right ventricle.decompressed. RV stroke work index and right atrial or
central venous pressure, which have previously been found
to be helpful (3,7,12), were not significant predictors in our
group perhaps, in part, because these variables are used at
our institution to delay LVAD surgery until management
can be altered, and to select patients for planned biventricular
support.
RV imaging is an attractive adjunct to clinical RV
evaluation because it is noninvasive and may offer greater
sensitivity to change than markers of pre-existing RV
failure. However, it is limited by the complex geometry of
the RV (20,28). RV size (assessed as RV-to-LV diameter
ratio) has previously been reported as a useful finding on
transesophageal echocardiography (6,11), but it was not
discriminatory in this group. Measures of RV systolic
performance range from subjective evaluation to fractional
area change and tricuspid annular systolic excursion. Tri-
cuspid excursion has been previously reported to have good
predictive value for RV failure (14), although such displace-
ment parameters may be influenced by the rocking motion
of the heart that may occur with severe LV dysfunction.
Longitudinal strain provides a direct measure of regional
deformation and may help to delineate more subtle abnor-
malities of RV contractility than other echo variables, such
as subjective RV function or fractional area change. Strain is
likely a composite measure of RV dysfunction and loading,
as decreased global RV strain is seen in patients with
pulmonary hypertension (23).
Study limitations. Significant differences in RV strain
were seen between those with and without RV failure. On
its own, however, the predictive value of this variable was
only modest, with a sensitivity of 68% and a specificity of
76%. These findings highlight the continued importance of
incorporating multiple factors into any method of risk
assessment. The number of events in our population limited
the number of parameters that could be incorporated into
our process of multivariate modeling. For this reason, we
focused on the analysis of RV strain as an adjunct to the
existing Michigan RV risk score.
Feasibility is an important limitation of the approach
described here for LVAD risk prediction. In this study, 26
of 143 clinically eligible patients (18%) were excluded
cted Echocardiographic Variablesore and Selected Echocardiographic Variables
5% CI) per SD OR (95% CI) p Value
(1.30–3.28) 1.48 (1.16–1.95) 0.01
(per 1-point increase)
(0.31–0.85) 0.86 (0.76–0.96) 0.01
(per 1% increase)
(0.50–1.33) 0.93 (0.78–1.11) 0.43
(per 1-mm increase)
(0.68–1.57) 1.02 (0.78–1.34) 0.89
(per increase of 0.1)Selesk Sc
OR (9
2.01
0.53
0.82
1.03because of insufficient or unavailable images, in most cases
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August 7, 2012:521–8 RV Assessment and Ventricular Assist Devices(n  23 [16%]) because of poor image quality. Further
xperience with the method may improve feasibility—
specially with obtaining dedicated views of the RV. How-
ver, this technique will likely remain unsuitable for patients
ith poor acoustic windows or very large RVs. Measure-
ents of strain are difficult in the thin-walled RV, which
ay contribute to the detection of only fair interobserver
greement using this technique. The relative merits of
ifferent strain measurement approaches are undefined; it is
ikely that different RV strain measures would be obtained
sing different software (29).
RV failure after LVAD implantation can be defined in a
ariety of ways, and criteria have varied considerably be-
ween reports. We selected a commonly employed defini-
ion that incorporates the perceived clinical significance of
evere RV dysfunction, but with the limitation of some
egree of subjectivity. The use of pulmonary vasodilators
uch as nitric oxide was not assessed, which might have led
o an underestimation of the number of patients who
equired intensive treatment for RV dysfunction. However,
n our study, the frequency of RV failure was in the upper
ange of what has been reported in the literature. This
nding may have been an artefact of local policies regarding
ggressive treatment with inotropes and early intervention
ith “rescue” RVADs to prevent the deleterious effects of
V failure. Less aggressive treatment at other centers might
ead to a lower incidence of RV failure. On the other hand,
ggressive treatment may have helped to mitigate some of
he risk associated with RV failure, perhaps contributing to
he lack of difference in mortality between patients with and
ithout RV failure in our study.
It should be acknowledged that this study was carried out
t a single institution. As such, the reproducibility of these
ndings in other populations remains untested. The neces-
ary exclusions from this study may also limit generalizabil-
ty. Because RV strain is a load-dependent measure, patients
ho were being supported with extracorporeal membrane
xygenation at the time of imaging were excluded from this
tudy, and the results cannot be extrapolated to this group.
e also excluded patients undergoing pulsatile LVAD
mplantation in order to reflect contemporary device ther-
py. The overwhelming majority of our patients received the
eartMate II LVAD. Although neither of the patients who
eceived the HeartWare LVAD experienced RV failure, the
umbers are too small to allow for extrapolation about the
ifferences between RV failure rates of the 2 devices.
This study tested the use of RV strain as a part of a
re-operative strategy for risk assessment. The utility of this
easurement in combination with other parameters as part
f an intraoperative strategy using transesophageal echocar-
iography has not been explored. Furthermore, the baseline
chocardiograms were obtained only under a single set of
emodynamic conditions, which varied between patients. It
s possible that the response of RV strain to changes in
reload, afterload, or contractility may provide additional
rognostic information.Conclusions
The findings from this study support the findings of
previous reports that RV failure is a common post-operative
issue after LVAD insertion. Global longitudinal strain of
the RV free wall represents a new parameter that may help
to predict the occurrence of this serious outcome in patients
receiving LVADs. It may be of value in making clinical
decisions about device selection for such patients in the
future, either in combination with other clinical factors,
such as those found in the Michigan risk score, or in other
risk-scoring systems.
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